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ABSTRACT	
Aims:	Physical	activity	is	protective	against	cardiovascular	(CV)	events,	both	in	general	
population	as	well	as	in	high-risk	CV	cohorts.	However,	the	relationship	between	physical	
activity	with	major	adverse	outcomes	in	atrial	fibrillation	(AF)	is	not	well-established.	Our	
aim	was	to	analyse	this	relationship	in	a	‘real-world’	AF	population.	Second,	we	investigated	
the	influence	of	physical	activity	on	arrhythmia	progression.	
Methods	and	Results:	We	studied	all	patients	enrolled	in	the	EURObservational	Research	
Programme	on	AF	(EORP-AF)	Pilot	Survey.	Physical	activity	was	defined	as	‘none’,	
‘occasional’,	‘regular’	and	‘intense’,	based	on	patient	self-reporting.	Data	on	physical	activity	
were	available	for	2,442	patients:	38.9%	reported	none,	34.7%	occasional,	21.7%	regular	
and	4.7%	intense	physical	activity.	Prevalence	of	the	principal	CV	risk	factors	progressively	
decreased	from	none	to	intense	physical	activity.		
Lower	rates	of	CV	death,	all-cause	death	and	composite	outcomes	were	found	in	AF	patients	
who	reported	regular	and	intense	physical	activity	(p<0.0001).	Increasing	physical	activity	
was	inversely	associated	with	CV	death/Any	thromboembolic	event	(TE)/bleeding	in	the	
whole	cohort,	irrespective	of	gender,	paroxysmal	AF,	elderly	age	or	high	stroke	risk.	Any	
level	of	physical	activity	intensity	was	significantly	associated	with	lower	risk	of	CV	
death/Any	TE/Bleeding	at	1-year	follow-up.	Physical	activity	was	not	significantly	associated	
with	arrhythmia	progression.	
Conclusions:		Atrial	fibrillation	patients	taking	regular	exercise	were	associated	with	a	lower	
risk	of	all-cause	death,	even	when	we	considered	various	subgroups,	including	gender,	
elderly	age,	symptomatic	status	and	stroke	risk	class.	Efforts	to	increase	physical	activity	
amongst	AF	patients	may	improve	outcomes	in	these	patients.	
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WHAT’S	NEW	
• Atrial	fibrillation	(AF)	patients	taking	regular	exercise	had	a	lower	rates	of	major	adverse	
outcomes;	
• Exercise	levels	in	AF	patients	are	inversely	associated	with	composite	outcomes	at	1-year	
follow-up;	
• Compared	with	patients	taking	no	physical	activity,	all	AF	patients	who	regularly	
exercised	had	a	tendency	towards	lower	risk	of	all-cause	death	at	1-year	follow-up.	
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INTRODUCTION	
Sedentary	lifestyle	is	a	major	risk	factor	for	cardiovascular	(CV)	disease1.	Accordingly,	
implementation	of	regular	physical	activity	has	been	identified	as	one	of	the	principal	public	
health	promotion	strategies	in	order	to	reduce	the	impact	of	risk	factors	on	CV	risk2,3.	
Indeed,	regular	physical	activity	has	been	associated	to	a	reduction	in	incident	CV	disease,	
CV	and	all-cause	death,	possibly	through	various	physiological	mechanisms4,5.	Moreover,	
the	influence	of	physical	activity	on	CV	morbidity	and	mortality	seems	to	go	beyond	
intensity,	with	the	same	beneficial	effect	also	with	light	physical	activity6.	
	
Atrial	fibrillation	(AF)	is	the	commonest	sustained	cardiac	arrhythmia	and	is	a	major	
contributor	to	CV	mortality	and	morbidity,	especially	from	thromboembolism	and	heart	
failure.		A	relationship	between	AF-related	adverse	outcomes	and	physical	activity	has	not	
been	established.	Data	investigating	the	effect	of	exercise	rehabilitation	or	chronic	exercise	
training	show	that	AF	patients	undergoing	structured	physical	activity	intervention	
programmes	reported	better	exercise	tolerance,	quality	of	life	and	less	intensive	clinical	
management7,8.		However,	the	influence	of	physical	activity	on	major	adverse	events	
occurring	in	the	long-term	follow-up	of	AF	patients	are	limited	and	inconclusive7.	
	
For	years,	physical	activity	has	been	reported	as	an	important	risk	factor	for	developing	AF	
both	in	athletes	and	general	population	and	regardless	of	its	intensity9.	On	the	basis	of	the	
available	evidence,	this	issue	seems	to	be	controversial.	A	large	comprehensive	systematic	
review	and	meta-analysis	reported	that	athletes,	exercising	in	several	different	sports,	have	
a	higher	risk	of	developing	AF,	with	a	more	than	five-fold	greater	risk	of	incident	AF	
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compared	with	controls10.		Furthermore,	observational	data	about	intensively	exercising	
athletes	(as	long-distance	skiers	or	professional	cyclists)	seem	to	corroborate	the	idea	that	
intensive	exercise	could	be	a	risk	factor	for	arrhythmias,	in	particular	AF11–13.		
	
Conversely,	one	large	observational	study	found	that	better	cardiorespiratory	fitness	(CRF)	
was	strongly	associated	with	a	reduced	risk	of	incident	AF	(hazard	ratio	[HR]:	0.92,	95%	
confidence	interval	[CI]:	0.91-0.93,	p<0.001	after	all	adjustments)	throughout	all	patient	
subgroups	and	with	a	clear	dose-effect	response14.	Another	large	cohort	study	on	structured	
weight-management	in	AF	obese	patients,	found	that	both	higher	baseline	CRF	level	and	a	
better	CRF	improvement	were	associated	with	a	reduced	risk	of	AF	recurrence15.	Other	
observational	studies	on	physical	activity	and	the	risk	of	incident	AF	demonstrated	that	this	
risk	was	different	across	gender	and	age	subgroups16,17.		In	male	subjects,	exercise	is	
associated	with	a	higher	risk	of	developing	AF	in	young	age,	while	is	inversely	associated	
with	AF	risk	in	the	elderly16.	In	women,	however,	exercise	did	not	increase	the	risk	of	
incident	AF	in	younger	subjects;	among	elderly	females,	the	association	between	exercise	
and	AF	remains17.	
	
The	aim	of	this	study	was	to	explore	the	relationship	between	self-reported	physical	activity	
and	major	adverse	events	in	AF	patients	prospectively	enrolled	in	the	EURObservational	
Research	Programme	on	AF	(EORP-AF)	Pilot	Survey.		Second,	we	explored	the	relation	of	
physical	activity	to	arrhythmia	progression	from	paroxysmal	AF	to	more	established	
patterns.		Third,	we	assessed	the	impact	of	physical	activity	in	relation	to	outcomes	by	sex,	
elderly	age	(age	≥75),	paroxysmal	AF	and	high	thromboembolic	risk.			
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METHODS	
The	EORP-AF	Pilot	study	was	an	observational	prospective	study	enrolling	consecutive	AF	
patients	managed	by	cardiologists,	conducted	by	the	European	Society	of	Cardiology	in	nine	
European	countries18.	Details	about	study	procedures18	and	main	results19	have	been	
previously	published.	
	
Patients	eligible	for	the	study	were	both	AF	inpatients	and/or	outpatients	referred	to	
cardiology	services	(either	hospital	or	office-based	centres).	Across	the	entire	enrolment	
period,	all	patients	consecutively	presenting	at	every	site	were	considered	for	eligibility.		AF	
had	to	be	recorded	as	a	primary	or	secondary	cardiovascular	disease.	Qualifying	events	
were	recorded	by	any	electrocardiographic	documentation	occurring	within	the	12	months	
before	the	enrolment.	Follow-up	data	were	recorded	1	year	after	the	enrolment	date.	Over	
13	months	of	enrolment,	a	total	of	3,119	AF	patients	were	collected.	All	patients	for	whom	
the	intensity	of	physical	activity	was	reported	were	considered	for	these	analyses.	
	
During	the	enrolment	interview,	patients	self-reported	their	level	of	physical	activity.	
According	to	patients’	reports,	physical	activity	over	the	preceding	2	years	was	defined	
according	to	its	intensity,	irrespective	of	type	of	activity,	as	follows:	(i)	‘None’	if	no	exercise	
or	exercise	was	for	<3	hours/week	for	<2	years;	(ii)	‘Occasional’	if	exercise	<3	hours/week	
for	≥2	years;	(iii)	‘Regular’	exercise	if	exercise	was	≥3	hours/week	for	≥2	years);	(iv)	‘Intense’	
exercise	if	physical	activity	was	reported	for	>7	hours/week	for	≥2	years.	Thromboembolic	
risk	was	assessed	according	to	the	Congestive	Heart	Failure-Hypertension-Age	≥75	years-
Diabetes	Mellitus-Stroke/transient	ischemic	attack	(TIA)/thromboembolism-Vascular	
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Disease-Age	65-74	years-Sex	category	(CHA2DS2-VASc)	score.	A	“high-risk”	AF	patient	was	
defined	as	a	CHA2DS2-VASc	score	≥220.	
	
Symptomatic	status	at	the	baseline	was	defined	according	to	European	Heart	Rhythm	
Association	(EHRA)	score21.	Accordingly,	patients	with	EHRA	I	were	considered	as	
asymptomatic,	while	EHRA	score	from	II	to	IV	described	patients	progressively	more	
symptomatic	and	unable	to	attend	their	usual	daily	activities21.	
	
During	the	pre-specified	1-year	follow-up	period,	the	occurrence	of	major	adverse	events	
was	recorded	with	office-based	follow-up	visits	according	to	patients’	self-reports,	
physicians’	letters	or	hospital	discharge	summaries.		According	to	the	study	protocol,	the	
following	events	were	recorded:	CV	death;	all-cause	death;	stroke/	TIA;	any	bleeding;	any	
thromboembolic	event	(TE)	(defined	as	the	occurrence	of	any	stroke,	TIA,	acute	coronary	
syndrome,	coronary	intervention,	cardiac	arrest,	peripheral	or	pulmonary	embolism).	
Composite	outcomes	of	the	major	adverse	events	previously	specified	were	also	considered.	
	
In	order	to	evaluate	the	influence	of	physical	activity	on	AF	progression,	we	evaluated	how	
many	patients	with	paroxysmal	AF	at	baseline	progressed	to	persistent,	long-standing	
persistent	or	permanent	AF	subtypes	based	on	clinical	examination,	and	ECGs	performed	
during	the	follow-up	period.			All	patients	with	paroxysmal	AF	who	at	the	1-year	follow-up	
visit	were	defined	as	persistent,	long-standing	persistent	or	permanent	AF	were	categorized	
as	“AF	progression”;	conversely,	all	patients	still	classified	as	paroxysmal	AF	at	1-year	were	
defined	as	“AF	non-progression”.	
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Statistical	Analysis	
Continuous	variables	were	reported	as	mean±SD	or	as	median	and	interquartile	range	(IQR).	
Among-group	comparisons	were	made	using	a	non-parametric	test	(Kruskal–Wallis	test).	
Categorical	variables	were	reported	as	percentages.	Among-group	comparisons	were	made	
using	a	chi-square	test	or	Fisher’s	exact	test	(if	any	expected	cell	count	was	less	than	five).	
For	qualitative	variables	with	more	than	two	possibilities,	the	Monte	Carlo	estimates	of	the	
exact	p-values	are	used.	
	
Plots	of	the	Kaplan-Meier	curves	for	time	to	all-causes	death	in	relation	to	physical	activity	
intensity	categories	were	performed.	The	survival	distributions	have	been	compared	using	
the	log-rank	test.	A	logistic	regression	analysis	was	performed	in	order	to	establish	the	
clinical	factors	significantly	associated	with	AF	progression.	All	variables	considered	of	
clinical	relevance	underwent	a	univariate	analysis	and	those	predictors	with	a	level	
significance	of	p<0.10	were	inserted	into	the	model.	A	significance	level	of	0.05	is	required	
to	allow	a	variable	into	the	model	(SLENTRY=0.05),	and	a	significance	level	of	0.05	is	
required	for	a	variable	to	stay	in	the	model	(SLSTAY=0.05).	No	interaction	was	tested.	A	
Hosmer	and	Lemeshow	Goodness-of-Fit	Test	was	used	to	verify	that	the	model	was	optimal.	
In	addition,	univariate	logistic	regression	analysis	on	the	effect	of	physical	activity	categories	
on	major	adverse	events	was	performed,	with	associations	expressed	as	odds	ratios	with	
95%	confidence	intervals,	comparing	the	categories	of	physical	activity	with	‘no	physical	
activity’	category	as	the	reference.	This	analysis	was	also	performed	stratified	according	to	
gender,	elderly	patients	(age≥75	years),	paroxysmal	AF	and	high	thromboembolic	risk	
(CHA2DS2-VASc	score	≥2).	A	two-sided	p	value	<0.05	was	considered	statistically	significant.	
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All	analyses	were	performed	using	SAS	statistical	software	version	9.3	(SAS	Institute,	Inc.,	
Cary,	NC,	USA).	
	
RESULTS	
From	the	original	study	population,	data	on	physical	activity	intensity	were	available	for	
2,442	patients	(78.5%).	Self-reported	physical	activity	was	as	follows:	38.9%	reported	none	
physical	activity,	whilst	34.7%	reported	occasional,	21.7%	regular	and	4.7%	intense	physical	
activity	(Table	1).		Of	the	selected	cohort,	979	(40.1%)	were	female	and	median	[IQR]	age	
was	70	[62-77]	years	(34.2%	were	aged	≥75	years);	42.3%	were	overweight	and	28.5%	of	
patients	were	obese.	Paroxysmal	AF	was	more	frequently	recorded	in	patients	with	intense	
physical	activity	(p<0.0001).	High	thromboembolic	risk	(CHA2DS2-VASc	score	≥2)	was	found	
in	81.6%	(1,993	patients).	
	
With	increasing	physical	activity	intensity	categories,	there	was	a	decrease	in	mean	age	and	
proportion	of	females,	as	well	as	in	those	with	hypertension,	diabetes	(all	p<0.0001)	and	
hypercholesterolemia	(p=0.019).	Conversely,	smoking	habit	was	less	prevalent	in	patients	
who	reported	no	physical	activity	(p=0.033).	The	proportion	of	obese	patients	was	lower	in	
the	intense	physical	activity	group	(p=0.008).	Patients	with	intense	physical	activity	had	a	
mean	higher	left	ventricular	ejection	fraction	(p=0.0420).	
	
Taking	into	account	co-morbidites	conditions,	patients	with	intense	physical	activity	
reported	a	lower	prevalence	of	coronary	artery	disease	(p=0.0024),	chronic	heart	failure	
(p<0.0001)	and	valvular	heart	disease	(p=0.0007).	Both	patients	with	regular	and	intense	
physical	activity	had	a	significant	lower	rate	of	previous	stroke	(p=0.0010).	
12	
	
Accordingly,	CHA2DS2-VASc	score	progressively	decreased,	as	did	the	proportion	at	‘high-
risk’	of	stroke/TE	(p<0.0001)	across	the	physical	activity	categories.		Patients	who	reported	
no	physical	activity	had	a	lower	proportion	of	EHRA	class	I	(asymptomatic	AF)	while	patients	
who	had	a	progressively	more	intense	physical	activity	were	more	likely	to	be	symptomatic	
at	EHRA	class	II-IV	(p<0.0001).	At	1-year	follow-up	pharmacological	cardioversion	(Table	2)	
was	progressively	more	used	across	the	four	physical	activity	categories	(p=0.0013).	
Electrical	cardioversion	and	catheter	ablation	were	more	likely	used	in	patients	with	regular	
and	intense	physical	activity	(both	p<0.0001).	
	
There	were	no	differences	in	the	proportion	of	patients	receiving	oral	anticoagulants	in	
relation	to	physical	activity	(p=0.619),	but	non-vitamin	K	antagonist	oral	anticoagulants	
were	more	often	used	in	the	intense	physical	activity	group	(p=0.005).		Patients	who	
reported	regular	and	intense	physical	activity	were	more	frequently	treated	with	at	least	
one	antiarrhythmic	drug	(p=0.001),	particularly	a	Class	I	antiarrhythmic	drug	(p<0.001).	AF	
patients	reporting	intense	physical	activity	were	less	frequently	treated	with	statins	
(p=0.002),	angiotensin-converting	enzyme	inhibitors/angiotensin	receptor	blockers	
(p<0.001),	diuretics	(p<0.0001),	aldosterone	blockers	(p<0.001)	and	digoxin	(p=0.004).	
	
Arrhythmia	Progression	and	Physical	Activity	
Of	the	632	(26.3%)	paroxysmal	AF	patients	at	baseline,	data	on	AF	subtype	at	1-year	were	
available	in	603	patients	(96.8%).	Of	these,	88	patients	(14.6%)	were	defined	as	“AF	
progression”	and	their	clinical	characteristics	were	similar	to	AF	non-progression	patients	
(Table	S1).		“AF	progression”	patients	were	older	(p=0.0226)	and	more	frequently	
underweight	(p=0.008).	The	proportion	of	“AF	progression”	patients	progressively	
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decreased	according	to	increasing	categories	of	physical	activity	intensity,	from	17.7%	in	
patients	reporting	no	physical	activity	to	6.8%	with	intense	physical	activity,	although	if	this	
difference	was	not	found	to	be	statistically	significant	(p=0.306).	Logistic	regression	found	
that	only	the	‘underweight’	category	was	independently	associated	with	AF	progression,	
while	intense	physical	activity	showed	an	inverse	trend	for	an	association	with	“AF	
progression”	(Table	3).	
		
Follow-up	Analysis	
During	the	1-year	follow-up	(Table	4),	patients	in	the	regular	and	intense	physical	activity	
categories	had	a	lower	prevalence	of	CV	death	and	all-cause	death	separately	(both	
p<0.0001),	as	well	as	the	composite	endpoint	of	“all-cause	death/any	TE”	(p<0.0001).	
Meanwhile	rates	for	the	composite	outcome	of	“CV	death/any	TE/bleeding”	progressively	
decreased	throughout	the	physical	activity	categories	(p<0.0001).	There	was	no	significant	
difference	in	rates	of	stroke/TIA	or	bleeding	by	self-reported	physical	activity	level.	
	
Univariate	logistic	regression	analysis	for	the	whole	cohort	(Table	5)	found	that	all	intensity	
levels	of	physical	activity	were	inversely	associated	with	the	composite	outcome	of	‘CV	
death/any	TE/bleeding’	(Figure	1).			Survival	analysis	demonstrates	that	patients	reporting	
any	physical	activity	intensity	level	had	lower	risk	for	all-cause	death	when	compared	to	
patients	reporting	none	physical	activity	(p<0.0001)	(Figure	2).			
	
Subgroup	Analyses	
A	gender-stratified	analysis	showed	similar	results,	compared	to	the	overall	cohort.	Both	
male	and	female	patients	in	the	‘none’	physical	activity	category	reported	higher	event	rates	
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for	CV	death	(p<0.0001	and	p<0.001,	respectively),	all-cause	death	(p<0.0001)	and	the	
composite	outcomes	(Table	S2).			Similar	results	were	obtained	for	elderly	(age≥75	years)	
patients,	paroxysmal	AF	and	high	thromboembolic	risk	(CHA2DS2-VASc	score	≥2)	patients	
(Table	S2).	
	
On	logistic	analysis	(Table	S3),	occasional	physical	activity	in	all	subgroups	was	inversely	
associated	with	the	composite	outcome	of	CV	death/Any	TE/Bleeding.	This	inverse	
association	was	significant	also	for	regular	physical	activity	in	all	subgroups,	except	for	
elderly	patients.	Intense	physical	activity	was	significantly	inversely	associated	with	the	
composite	outcome	only	for	male	patients	(p=0.025),	while	in	the	other	subgroups	this	was	
non-significant.		Similar	to	the	overall	population,	survival	analysis	in	the	various	subgroups	
showed	that	the	none	physical	activity	conferred	a	higher	risk	for	all-cause	death	compared	
to	patients	reporting	any	intensity	level	of	physical	activity	(p<0.0001).	
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DISCUSSION	
	
Our	study	provides	the	first	evidence	that	AF	patients	exercising	at	any	level	of	intensity	
have	a	lower	risk	of	all-cause	death	compared	to	AF	patients	with	no	physical	activity	on	a	
long-term	follow-up	observation.		Second,	the	composite	outcome	of	CV	death/any	
TE/bleeding	was	inversely	proportional	to	intensity	of	self-reported	physical	activity.	Third,	
the	proportion	of	“AF	progression”	decreased	as	the	intensity	of	physical	activity	increased	
but	not	significantly,	with	no	significant	evidence	that	more	intensive	physical	activity	was	
associated	with	less	arrhythmia	progression.	Last,	the	association	between	physical	activity	
and	the	reduced	risk	of	all-cause	death	was	significant	regardless	of	gender,	older	age	(≥75	
years),	presence	of	paroxysmal	AF	and	high	thromboembolic	risk	(CHA2DS2-VASc	score	≥2).		
	
The	beneficial	effect	of	physical	activity	on	CV	death	and	all-cause	death	in	the	general	
population	has	been	shown.		For	example,	the	Framingham	Heart	Study	reported	that	
among	4,729	free	from	CV	disease	at	baseline,	long-term	physical	activity	was	inversely	
associated	with	lower	all-cause	death	(rate	ratio	0.81,	95%	CI	0.71-0.93)	and	CVD-
attributable	mortality	(rate	ratio	0.83,	95%	CI	0.72-0.97)	over	40	years	follow-up22.	A	large	
prospective,	observational	cohort,	the	Aerobics	Center	Longitudinal	Study	demonstrated	
that	leisure-time	running	was	associated	with	a	reduced	risk	for	both	all-cause	and	CV	death	
in	55,137	subjects	followed	for	a	mean	follow-up	of	15	years6.		Reduced	risks	were	evident	
across	the	different	classes	of	running	categories	(running	distance,	running	frequency,	total	
amount	of	running	and	running	speed)6.	
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Our	data	show	for	the	first	time	in	a	large	European	AF	population	that	occasional,	regular	
or	intense	physical	activity	was	associated	with	a	reduced	risk	of	all-cause	death	and	
inversely	associated	with	the	composite	outcome	of	CV	death/any	TE/bleeding.	This	
evidence	supports	previous	data	of	the	impact	of	physical	activity	on	secondary	CV	
prevention5.	Both	observational	and	randomized	controlled	trials	have	shown	that	physical	
activity,	as	well	as	structured	rehabilitation	programmes,	are	associated	with	improvements	
in	all	CV	associated	risk	factors,	and	also	in	reductions	in	CV	morbidity	and	mortality5.			
Indeed,	our	findings	underline	the	important	role	of	physical	activity	in	the	management	of	
CV	risk,	and	specifically,	in	patients	with	AF.		
	
The	inverse	association	between	progressively	more	intensive	physical	activity	and	reduced	
outcomes	rates,	as	long	as	its	hypothesized	beneficial	effect,	as	shown	by	our	data	could	be	
simply	explained	by	the	exercise	effect	in	reducing	CV	risk.	Recently,	improved	
cardiorespiratory	fitness	(CRF)	has	been	related	to	reduced	incidence	of	CV	events,	CV	death	
and	all-cause	death,	beyond	the	physical	activity	itself	and	weight	reduction23.	In	the	
Aerobics	Center	Longitudinal	Study,	the	incremental	value	of	CRF	was	associated	with	a	
progressive	decrease	in	all-cause	and	CV	death,	regardless	of	both	body	weight	and	body	fat	
reductions23.	The	role	of	CRF	may	be	considered	as	crucial	in	the	relationship	between	
physical	activity,	body	weight	and	CV	risk,	both	in	the	general	population	and	high-risk	CV	
patients4.		Our	data	demonstrating	a	similar	relationship	between	physical	activity	and	
reduced	adverse	events	in	all	subgroups	considered,	also	strengthens	the	possible	role	of	
physical	activity	in	reducing	adverse	events	in	AF	patients,	regardless	of	their	clinical	
characteristics	and	presentation.	Conversely,	physical	activity	could	represent	a	major	
marker	of	health	status	in	AF	patients,	and	indeed,	those	undertaking	intense	physical	
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activity	had	less	risk	factors	and	comorbidities,	as	well	as	a	lower	thromboembolic	risk	
overall.	Therefore,	healthier	subjects	(with	a	lower	risk	of	major	adverse	events)	would	be	
more	easily	prone	to	taking	more	exercise.	
	
Evidence	about	the	relationship	between	physical	activity	and	AF	has	largely	been	
controversial.	Several	studies	report	a	direct	association	between	physical	activity	and	the	
occurrence	of	incident	AF9,16,17;	conversely,	some	large	well-controlled	trials	suggest	that	
physical	activity	seems	to	be	protective	both	in	terms	of	incident	AF14,	recurrence	of	AF15	
and	AF	burden.		One	national	cohort	observational	study	examining	about	the	role	of	
physical	activity	in	the	occurrence	of	both	vascular	events	and	arrhythmias,	found	that	over	
a	long	term	follow-up	of	26.3	years,	high	exercise	capacity	was	associated	both	with	
reduced	vascular	events	(HR:	0.67,	95%	CI	0.65-0.70)	and	the	occurrence	of	arrhythmia	
episodes	(HR:	0.92,	95%	CI:	0.88-0.97)24.	However,	no	significant	association	was	found	in	
regard	to	the	occurrence	of	AF	episodes.		In	a	recent	interventional	randomized	trial,	
aerobic	interval	activity	reduced	AF	burden	in	patients	with	non-permanent	AF,	at	least	over	
short-term	follow-up	25.		In	the	present	study,	our	results	show	that	despite	a	gradual	
reduction	in	the	proportions	of	AF	progression	across	the	categories	of	physical	activity	
intensity,	this	difference	in	proportions	was	not	statistically	significant.		Also,	our	analyses	
were	not	able	to	document	an	independent	association	between	any	physical	activity	
intensity	category	and	AF	progression.		
	
Interestingly,	patients	with	intense	physical	activity	were	more	frequently	diagnosed	with	
paroxysmal	AF.	They	were	also	more	symptomatic,	more	frequently	treated	with	at	least	
one	antiarrhythmic	drug	or	interventions	aimed	to	restore	sinus	rhythm.	Even	if	these	
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findings	seem	to	be	inconsistent	with	previous	findings	showing	that	physical	activity	helps	
improve	symptoms	7,15,	perhaps	with	a	dose-response	relationship	15,	this	could	reflect	a	
protective	action	of	physical	activity	in	preventing	AF	recurrence	and	burden15,25.	Indeed,	
even	if	non-significant,	there	was	a	trend	for	an	inverse	association	between	intense	
physical	activity	and	AF	progression.	On	the	other	hand	the	higher	prevalence	of	paroxysmal	
AF	in	patients	with	intense	physical	activity	could	simply	reflect	that	being	more	frequently	
in	sinus	rhythm,	those	patients	were	more	easily	prone	to	increased	exercise.	
	
Strengths	and	Limitations	
The	strength	of	our	data	is	the	“real	world	population”	of	AF	patients	who	were	
consecutively	recruited	by	European	cardiologists.	Conversely,	the	latter	may	not	
completely	represent	the	AF	population	managed	by	non-cardiologists.	One	major	limitation	
is	clearly	represented	by	the	self-reported	nature	of	the	data	on	physical	activity.	Moreover,	
the	lack	of	specific	details	about	the	type	and	frequency	of	physical	activity	further	
underlines	this	limitation.	Likewise,	given	the	observational	nature	of	the	study,	more	
reliable	quantification	of	physical	activity	as	the	metabolic	equivalents	were	not	available.	
Furthermore,	the	relatively	short	follow-up	period	and	generally	low	rate	of	major	adverse	
events	could	have	limited	power	to	associate	physical	activity	with	events,	in	particular	to	
detect	survival	differences	in	patient	subgroups.	Lastly,	EORP-AF	was	an	observational	study	
and	was	not	powered	to	detect	survival	differences	in	different	patient	subgroups;	
moreover,	we	cannot	imply	a	causal	relationship	between	physical	activity	and	event	rates.		
Thus,	our	data	are	not	intended	to	be	as	a	proof	of	the	“protective	effect”	of	physical	
activity	in	AF	patients,	but	to	be	considered	as	hypothesis-generating.		Further	
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interventional	trials	in	the	AF	population,	with	adequate	recording	of	physical	activity	and	
properly	powered	to	detect	differences	in	survival,	are	needed.	
	
CONCLUSIONS	
Patients	with	AF	taking	regular	exercise	seem	to	report	a	significant	tendency	in	lower	risk	
of	all-cause	death,	regardless	of	gender,	elderly	age,	clinical	presentation	and	stroke	risk	
class.	Physical	activity	was	not	independently	associated	with	AF	progression.	Efforts	to	
increase	physical	activity	amongst	AF	patients	may	improve	outcomes	in	these	patients.	
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APPENDIX:	AF	General	Pilot	Registry	Investigators	
Executive	Committee:	Gregory	Y.H.	Lip,	Luigi	Tavazzi,	Aldo	P.	Maggioni,	Harry	JGM	Crijns,	
Paulus	Kirchhof,	and	Panos	Vardas.		
Steering	Committee	(National	Coordinators):	Gheorghe-Andrei	Dan,	Dan	Atar,	Emmanuel	
Simantirakis,	Massimo	Santini,	Zbigniew	Kalarus,	Lars	Hvilsted	Rasmussen,	Mário	Martins	
Oliveira,	and	Georges	Mairesse.	
Data	monitor	and	technical	support	team:	Data	collection	was	conducted	by	the	
EURObservational	Research	Program	Department	from	the	European	Cardiac	Society	by	
Viviane	Missiamenou.	Statistical	analyses	were	performed	by	Cécile	Laroche	with	the	
support	of	Renato	Urso.	Overall	activities	were	coordinated	by	Aldo	P.	Maggioni	(Scientific	
Coordinator	EORP)	and	Thierry	Ferreira	(Head	of	Department	EORP).	
	
Investigators:	BELGIUM	Bastogne:	M.	Raepers,	Z.	el	Husseini;	Hasselt:	D.	Dilling-Boer,	J.	
Schurmans,	J.	Vijgen,	P.	Koopman;	Wilrijk:	W.	Huybrechts;	Yvoir:	F.	Dormal,	D.	Blommaert,	
O.	Deceuninck,	O.	Xhaet;	DENMARK	Aalborg:	C.	Fragtrup	Hellum,	B.	Mortensen,	B.	Ginnerup	
Sorensen,	A.	M.	Joensen,	Sam	Riahi,	L.	H.	Rasmussen;	Copenhagen:	A.	Karlsdottir,	S.	
Pehrson;	Esbjerg:	J.	Hummelshoj,	A-M.	Svenningsen,	L.	Tanggaard,	P.Wiggers,	A.	Nygaard;	
Hjorring:	A.	Jonstrup,	J.	Petersen;	Silkeborg:	A.	Odgaard,	M.	Mortensen,	L.	Frost;	Viborg:	D.	
Svenstrup	Møller,	H.M.	Søndergaard,	P.	D.	Christensen;	GREECE	Athens:	S.	Xydonas,	L.	Lioni;	
Chios:	M.	Dimopoulou,	G.	Georgiopoulos,	E.	Papatheodorou,	P.	Boutas,	A.	Kartalis;	
Heraklion:	P.	Vardas,	H.	Nakou,	E.	Kanoupakis,	E.	Simantirakis;	Thessaloniki:	D.	Tahmatzidis,	
I.	Styliadis,	V.	Vassilikos;	Thessaloniki:	K.	Koskinas,	N.	Fragakis;	Thessaloniki:	K.	
Polymeropoulos,	G.	Maligos;	ITALY	Bologna:	C.	Martignani,	I.	Diemberger,	G.	Boriani,	J.	
Frisoni,	M.	Biffi,	M.	Ziacchi,	P.	Cimaglia,	E.	Fantecchi;	Firenze:	S.	Boni,	D.	Gabbai,	N.	
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Table	1:	Baseline	Characteristics	of	Patients	According	to	Physical	Activity	Intensity	
	
None	
n=949	
Occasional	
n=848	
Regular	
n=530	
Intense	
n=115	 p	
Demographics	 	 	 	 	 	
Age	years,	Median	(IQR)	 74	(66-80)	 69	(62-77)	 65	(58-72)	 64	(56-72)	 <0.0001	
Age	≥75	years,	n	(%)	 453	(47.7)	 276	(32.5)	 85	(16.0)	 21	(18.3)	 <0.0001	
Female	Gender,	n	(%)	 462	(48.7)	 349	(41.2)	 140	(26.4)	 28	(24.3)	 <0.0001	
BMI,	n	(%)	2,389	 	 	 	 	 0.008	
Underweight	 16	(1.7)	 9	(1.1)	 2	(0.4)	 0	 	
Normal	 271	(29.6)	 216	(25.8)	 145	(27.7)	 40	(35.4)	 	
Overweight	 373	(40.7)	 348	(41.6)	 235	(44.9)	 54	(47.8)	 	
Obese	 257	(28.0)	 263	(31.5)	 141	(27.0)	 19	(16.8)	 	
LVEF	%,	Mean±SD	 52.5±14.4	 52.0±13.0	 52.6±13.0	 55.8±12.2	 0.0420	
AF	Subtypes,	n	(%)	2,403	 	 	 	 	 <0.0001	
First	Detected	 311	(33.1)	 235	(28.4)	 169	(32.4)	 25	(21.9)	 	
Paroxysmal	 202	(21.5)	 240	(29.0)	 146	(28.0)	 44	(38.6)	 	
Long-Standing	Persistent	 32	(3.4)	 55	(6.6)	 16	(3.1)	 6	(5.3)	 	
Persistent	 175	(18.6)	 173	(20.9)	 126	(24.1)	 21	(18.4)	 	
Permanent	 219	(23.3)	 125	(15.1)	 65	(12.5)	 18	(15.8)	 	
Cardiovascular	Risk	Factors,	n	(%)	 	 	 	 	 	
Diabetes	Mellitus	2,430	 226	(24.0)	 178	(21.1)	 77	(14.6)	 15	(13.2)	 <0.0001	
Hypertension	2,431	 694	(73.5)	 643	(76.1)	 335	(63.3)	 57	(50.4)	 <0.0001	
Current	Smoker	2,407	 84	(8.9)	 101	(12.1)	 71	(13.6)	 13	(11.7)	 0.033	
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None	
n=949	
Occasional	
n=848	
Regular	
n=530	
Intense	
n=115	 p	
Hypercholesterolemia	2,398	 466	(50.2)	 423	(50.7)	 230	(43.9)	 45	(40.5)	 0.019	
Alcohol	≥2-3	units/day	2,356	 64	(7.0)	 59	(7.2)	 56	(11.0)	 14	(13.0)	 0.010	
Concomitant	Conditions,	n	(%)	 	 	 	 	 	
Coronary	Artery	Disease	2,117	 329	(39.2)	 271	(37.3)	 145	(31.8)	 22	(23.2)	 0.0024	
Chronic	Heart	Failure	2,324	 453	(49.0)	 416	(51.1)	 200	(41.4)	 28	(27.2)	 <0.0001	
Valvular	Heart	Disease	2,299	 620	(67.9)	 524	(64.9)	 282	(58.4)	 52	(54.2)	 0.0007	
Dilated	Cardiomyopathy	2,311	 106	(11.5)	 107	(13.2)	 50	(10.4)	 5	(5.0)	 0.0750	
HCM	2,315	 32	(3.5)	 39	(4.8)	 18	(3.7)	 3	(3.0)	 0.5125	
Previous	Stroke	2,429	 77	(8.1)	 53	(6.3)	 15	(2.9)	 6	(5.3)	 0.0010	
Previous	TIA	2,421	 48	(5.1)	 29	(3.5)	 17	(3.2)	 5	(4.4)	 0.2363	
PVD	2,310	 130	(14.0)	 88	(11.2)	 58	(11.7)	 6	(5.9)	 0.0610	
CHA2DS2-VASc	score	 	 	 	 	 	
Mean	score	±	SD	 3.79	±1.74	 3.31	±1.73	 2.44	±1.68	 2.17	±1.78	 <0.0001	
CHA2DS2-VASc	class,	n	(%)	 	 	 	 	 <0.0001	
Class	0	 22	(5.8)	 35	(4.1)	 65	(12.3)	 19	(16.5)	 	
Class	1	 76	(8.0)	 103	(12.1)	 101	(19.1)	 29	(25.2)	 	
Class	≥2	 851	(89.7)	 710	(83.7)	 364	(68.7)	 67	(58.3)	 	
EHRA	score,	n	(%)	
EHRA	I	
EHRA	II-IV	
	
479	(50.5)	
470	(49.5)	
	
319	(37.6)	
529	(62.4)	
	
173	(32.6)	
357	(67.3)	
	
34	(29.6)	
81	(70.4)	
<0.0001	
30	
	
	
None	
n=949	
Occasional	
n=848	
Regular	
n=530	
Intense	
n=115	 p	
Drug	Therapy	at	Discharge/After	
Consultation	
	 	 	 	 	
Antithrombotic	therapy,	n	(%)	 	 	 	 	 	
At	least	one	2,438	 911	(96.1)	 823	(97.2)	 498	(94.3)	 110	(95.7)	 0.071	
Antiplatelet	2,438	 296	(31.2)	 312	(36.8)	 179	(33.9)	 30	(26.1)	 0.025	
Oral	anticoagulant	2,437	 761	(80.4)	 697	(82.3)	 430	(81.4)	 97	(84.3)	 0.619	
NOACs	2,439	 63	(6.6)	 60	(7.1)	 45	(8.5)	 18	(15.7)	 0.005	
Antiarrhythmic	drugs,	n	(%)	2,441	 	 	 	 	 	
At	least	one	 289	(30.5)	 306	(36.1)	 215	(40.6)	 45	(39.1)	 <0.001	
Antiarrhythmic	Class	I	 73	(7.7)	 80	(9.4)	 68	(12.8)	 19	(16.5)	 0.001	
Antiarrhythmic	Class	III	 217	(22.9)	 224	(26.4)	 152	(28.7)	 26	(22.6)	 0.066	
Other	treatments,	n	(%)	 	 	 	 	 	
Statins	2,437	 443	(46.7)	 453	(53.5)	 243	(46.1)	 45	(39.1)	 0.002	
ACEi/ARBs	2,438	 609	(64.4)	 587	(69.3)	 324	(61.1)	 60	(52.2)	 <0.001	
Beta	blockers	2,437	 637	(67.3)	 611	(72.2)	 379	(71.5)	 76	(66.1)	 0.0870	
Diuretics	2,439	 564	(59.6)	 458	(54.1)	 221	(41.7)	 30	(26.1)	 <0.0001	
Aldosterone	blockers	2,439	 269	(28.4)	 209	(24.7)	 121	(22.8)	 12	(10.4)	 <0.001	
DHP	calcium-channel	blockers	
2,439	
118	(12.4)	 125	(14.8)	 75	(14.2)	 7	(6.1)	 0.053	
Non-DHP	calcium-channel	
blockers	2,439	
75	(7.9)	 43	(5.1)	 28	(5.3)	 7	(6.1)	 0.064	
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None	
n=949	
Occasional	
n=848	
Regular	
n=530	
Intense	
n=115	 p	
Digoxin	2,440	 208	(21.9)	 169	(20.0)	 86	(16.2)	 12	(10.4)	 0.004	
DRI	Aliskiren	2,439	 2	(0.2)	 0	 2	(0.4)	 0	 0.358*	
Oral	anti-diabetics	2,441	 157	(16.5)	 121	(14.3)	 59	(11.1)	 10	(8.7)	 0.011	
Insulin	2,441	 58	(6.1)	 44	(5.2)	 17	(3.2)	 4	(3.5)	 0.085	
Thyroid-suppressing	drugs	
2,441	
22	(2.3)	 17	(2.0)	 16	(3.0)	 6	(5.2)	 0.169	
Beta-2	agonists	2,441	 21	(2.2)	 11	(1.3)	 6	(1.1)	 1	(0.9)	 0.274	
Anticholinergic	agents	2,441	 34	(3.6)	 15	(1.8)	 5	(0.9)	 0	 0.001	
Legend:	ACEi=	angiotensin-converting	enzyme	inhibitors;	ARBs=	angiotensin	receptor	
blockers;	BMI=	body	mass	index;	DHP=	dihydropyridine;	DRI=	direct	renin	inhibitor;	HCM=	
hypertrophic	cardiomyopathy;	IQR=	interquartile	range;	LVEF=	left	ventricular	ejection	
fraction;	NOACs=	non-vitamin	k	antagonist	oral	anticoagulants;	PVD=	peripheral	vascular	
disease;	SD=	standard	deviation;	TIA=	transient	ischemic	attack.	*Fisher’s	exact	test.		
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Table	2:	Interventions	at	1-year	Follow-up	According	to	Physical	Activity	Intensity	
	 None	
n=949	
Occasional	
n=848	
Regular	
n=530	
Intense	
n=115	 p	
Pharmacological	Cardioversion	 52	(6.3%)	 78	(9.6)	 58	(11.2)	 17	(15.3)	 0.0013	
Electrical	Cardioversion	 32	(4.0)	 30	(3.8)	 34	(6.8)	 14	(12.8)	 <0.0001	
Catheter	Ablation	 18	(2.2)	 29	(3.6)	 36	(6.9)	 8	(7.1)	 <0.0001	
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	 Table	3:	Logistic	Regression	Analysis	for	AF	Progression	Occurrence	
	
Univariate	Analysis	
M
ultivariable	Analysis	
	
Odds	Ratio	
95%
	CI	
p	
Odds	Ratio	
95%
	CI	
p	
Age	(in	years)	
1.021	
[1.000-1.043]	
0.046	
-	
-	
-	
Fem
ale	Gender	
0.943	
[0.596-1.493]	
0.803	
-	
-	
-	
BM
I	(ref.	Norm
al)	
Underw
eight	
O
verw
eight	
O
bese	
	
13.400	
0.671	
0.578	
	
[1.347-133.325]	
[0.394-1.142]	
[0.308-1.087]	
	
0.022	
-	-	
	
13.832	
0.657	
0.531	
	
[1.377-138.979]	
[0.384-1.122]	
[0.281-1.003]	
	
0.026	
0.124	
0.051	
Diabetes	
0.635	
[0.316-1.276]	
0.202	
-	
-	
-	
Hypertension	
1.266	
[0.759-2.110]	
0.366	
-	
-	
-	
Current	sm
oker	
1.105	
[0.569-2.145]	
0.768	
-	
-	
-	
Hypercholesterolem
ia	
1.295	
[0.819-2.046]	
0.269	
-	
-	
-	
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	 Legend:	CI=	confidence	interval;	ref=	reference.	
Physical	Activity	(ref.	None)	
Occasional	
Regular	
Intense	
	
0.761	
0.757	
0.341	
	
[0.448-1.293]	
[0.412-1.390]	
[0.099-1.169]	
	
0.327	
-	-	
	
0.720	
0.700	
0.310	
	
[0.417-1.241]	
[0.374-1.313]	
[0.089-1.078]	
	
0.237	
0.267	
0.066	
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Table	4:	Major	Adverse	Events	During	1-year	Follow-up	According	to	Physical	Activity	
Categories	
	
None	
n=949	
Occasional	
n=848	
Regular	
n=503	
Intense	
n=115	 p	
Major	Adverse	Events,	n	(%)	 	 	 	 	 	
Stroke/TIA	 9	(1.1%)	 9	(1.2%)	 2	(0.4%)	 1	(1.0%)	 0.426*	
Bleeding	 13	(1.7%)	 9	(1.2%)	 3	(0.6%)	 0	 0.235*	
Any	TE	 34	(4.3%)	 25	(3.4%)	 21	(4.2%)	 3	(2.9%)	 0.733*	
CV	death	 53	(5.8%)	 12	(1.4%)	 2	(0.4%)	 1	(0.9%)	 <0.0001*	
All-cause	death	 116	(12.2%)	 33	(3.9%)	 7	(1.3%)	 3	(2.6%)	 <0.0001*	
All-cause	death/Any	TE	 150	(16.6%)	 58	(7.5%)	 28	(5.5%)	 6	(5.6%)	 <0.0001	
CV	death/Any	TE/Bleeding	 99	(12.0%)	 45	(6.1%)	 26	(5.2%)	 4	(3.8%)	 <0.0001*	
Legend:	CV=	cardiovascular;	TE=	thromboembolic	event;	TIA=	transient	ischemic	attack;	
*Fisher’s	exact	test.	
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Table	5:	Effect	of	Physical	Activity	Categories	on	Major	Adverse	Events			
Physical	Activity	 1-year	outcome	 Whole	Cohort	
	 	 Odds	Ratio*	 95%	CI	 p	
Occasional	 Stroke/TIA	 1.07	 [0.42-2.71]	 0.885	
	 Any	TE	 0.78	 [0.46-1.32]	 0.353	
	 Bleeding	 0.72	 [0.51-1.03]	 0.07	
	 CV	death/Any	TE/Bleeding	 0.48	 [0.33-0.69]	 <0.0001	
Regular	 Stroke/TIA	 0.35	 [0.07-1.62]	 0.159	
	 Any	TE	 0.97	 [0.56-1.70]	 0.923	
	 Bleeding	 0.75	 [0.47-1.19]	 0.218	
	 CV	death/Any	TE/Bleeding	 0.40	 [0.26-0.63]	 <0.0001	
Intense	 Stroke/TIA	 0.83	 [0.10-6.65]	 0.864	
	 Any	TE	 0.65	 [0.20-2.17]	 0.484	
	 Bleeding	 0.49	 [0.17-1.37]	 0.169	
	 CV	death/Any	TE/Bleeding	 0.29	 [0.10-0.80]	 0.011	
Legend:	*Analysis	presented	is	unadjusted	univariate	logistic	analysis.	CI=	confidence	
interval;	CV=	cardiovascular;	NA=	not	available;	TE=	thromboembolic	event;	TIA=	transient	
ischemic	attack.	
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FIGURE	LEGENDS	
Figure	1:	Univariate	Logistic	Analysis	for	Major	Adverse	Events	
Legend:	TE:	thromboembolic	event;	TIA=	transient	ischemic	attack.	
Figure	2:	Kaplan-Meier	Curves	for	All-Cause	Death
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Table	S1:	Baseline	Characteristics	of	Patients	According	to	AF	Progression	
	
AF	Progression	
n=88	
AF	Non-Progression	
n=515	 p	
Demographics	 	 	 	
Age	in	years	Median	(IQR)	 70	(62-76)	 66	(59-74)	 0.023	
Age	≥75	years,	n	(%)	 29	/	88	(33.0)	 120	/	515	(23.3)	 0.052	
Female	gender,	n	(%)	 36	/	88	(40.9)	 218	/	515	(42.3)	 0.803	
BMI,	n	(%)	 	 	 0.008	
Underweight	 3	/	86	(3.5)	 1	/	507	(0.2%)	 	
Normal	 30	/	86	(34.9)	 134	/	507	(26.4%)	 	
Overweight	 35	/	86	(40.7)	 233	/	507	(46.0%)	 	
Obese	 18	/	86	(20.9)	 139	/	507	(27.4%)	 	
Cardiovascular	Risk	Factors,	n	(%)	 	 	 	
Diabetes	Mellitus	 10	/	88	(11.4)	 86	/	512	(16.8)	 0.199	
Hypertension	 65	/	88	(73.9)	 355	/	514	(69.1)	 0.365	
Current	Smoker	 12	/	86	(14.0)	 65	/	508	(12.8)	 0.767	
Hypercholesterolemia	 45	/	86	(52.3)	 234	/	510	(45.9)	 0.268	
Alcohol	≥2-3	units/day	 6	/	86	(7.0)	 24	/	503	(4.8)	 0.423*	
CHA2DS2-VASc	score	 	 	 0.306	
Mean	score	±	SD	 2.9	±1.6	 2.7	±1.8	 	
CHA2DS2-VASc	class,	n	(%)	 	 	 0.025	
Class	0	 6	/	88	(6.8)	 45	/	515	(8.7)	 	
Class	1	 9	/	88	(10.2)	 111	/	515	(21.6)	 	
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AF	Progression	
n=88	
AF	Non-Progression	
n=515	 p	
Class	≥2	 73	/	88	(83.0)	 359	/	515	(69.7)	 	
Drug	Therapy	at	Discharge/After	
Consultation	
	 	 	
Antithrombotic	Therapy,	n	(%)	 	 	 	
At	least	one	 84	/	88	(95.5)	 490	/	515	(95.1)	 >0.999	
Antiplatelet	 19	/	88	(21.6)	 178	/	514	(34.6)	 0.016	
Oral	anticoagulant	 75	/	88	(85.2)	 397	/	514	(77.2)	 0.092	
NOACs	 5	/	88	(5.7)	 39	/	515	(7.6)	 0.529	
Antiarrhythmic	Drugs,	n	(%)	 	 	 	
At	least	one	 45	/	88	(51.1)	 252	/	515	(48.9)	 0.702	
Antiarrhythmic	class	I	 15	/	88	(17.0)	 98	/	515	(19.0)	 0.659	
Antiarrhythmic	class	III	 29	/	88	(33.0)	 155	/	515	(30.1)	 0.591	
Other	Treatments,	n	(%)	 	 	 	
Statins	 46	/	88	(52.3)	 259	/	514	(50.4)	 0.744	
ACEi/ARBs	 63	/	88	(71.6)	 317	/	512	(61.9)	 0.082	
Beta	blockers	 58	/	88	(65.9)	 352	/	514	(68.5)	 0.632	
Diuretics	 33	/	88	(37.5)	 185	/	514	(36.0)	 0.786	
Aldosterone	blockers	 10	/	88	(11.4)	 55	/	514	(10.7)	 0.853	
DHP	calcium-channel	blockers	 11	/	88	(12.5)	 76	/	514	(14.8)	 0.573	
Non-DHP	calcium-channel	blockers	 5	/	88	(5.7)	 21	/	514	(4.1)	 0.567*	
Digoxin	 3	/	88	(3.4)	 27	/	514	(5.3)	 0.602*	
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AF	Progression	
n=88	
AF	Non-Progression	
n=515	 p	
Oral	anti-diabetics	 8	/	88	(9.1)	 61	/	515	(11.8)	 0.453	
Insulin	 2	/	88	(2.3)	 18	/	515	(3.5)	 0.753*	
Thyroid-suppressing	drugs	 4	/	88	(4.5)	 11	/	515	(2.1)	 0.254*	
Beta-2	agonists	 -	 2	/	515	(0.4)	 >0.999*	
Anticholinergic	agents	 -	 4	/	515	(0.8)	 >0.999*	
Legend:	ACEi=	angiotensin-converting	enzyme	inhibitors;	ARBs=	angiotensin	receptor	
blockers;	BMI=	body	mass	index;	DHP=	dihydropyridine;	DRI=	direct	renin	inhibitor;	IQR=	
interquartile	range;	NOACs=	non-vitamin	k	antagonist	oral	anticoagulants.	*Fisher’s	exact	
test.	
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Table	S2:	Major	Adverse	Events	Rate	According	to	Physical	Activity	in	Subgroups	at	1-Year	
FU	
	 None	 Occasional	 Regular	 Intense	 p	
Male	Patients	 	 	 	 	 	
N°	of	patients	 487	 499	 390	 87	 	
Major	Adverse	Events,	n	(%)	 	 	 	 	 	
Stroke/TIA	 4	(1.0%)	 4	(0.9%)	 2	(0.5%)	 1	(1.2%)	 0.750	
Bleeding	 8	(2.0%)	 6	(1.4%)	 2	(0.5%)	 0	 0.277	
Any	TE	 15	(3.7%)	 16	(3.7%)	 20	(5.3%)	 2	(2.5%)	 0.497	
CV	death	 28	(6.0%)	 9	(1.8%)	 1	(0.3%)	 1	(1.2%)	 <0.0001	
All-cause	death	 65	(13.3%)	 24	(4.8%)	 4	(1.0%)	 2	(2.3%)	 <0.0001	
All-cause	death	/Any	TE	 80	(17.0%)	 40	(8.7%)	 24	(6.3%)	 4	(4.8%)	 <0.0001	
CV	death/Any	TE/Bleeding	 51	(12.0%)	 30	(6.9%)	 23	(6.2%)	 3	(3.7%)	 0.004	
	 	 	 	 	 	
Female	Patients	 	 	 	 	 	
N°	of	patients	 462	 349	 140	 28	 	
Major	Adverse	Events,	n	(%)	 	 	 	 	 	
Stroke/TIA	 5	(1.3%)	 5	(1.6%)	 0	 0	 0.611	
Bleeding	 5	(1.3%)	 3	(1.0%)	 1	(0.8%)	 0	 0.927	
Any	TE	 19	(4.9%)	 9	(3.0%)	 1	(0.8%)	 1	(4.2%)	 0.110	
CV	death	 25	(5.6%)	 3	(0.9%)	 1	(0.7%)	 0	 <0.001	
All-cause	death	 51	(11.0%)	 9	(2.6%)	 3	(2.1%)	 1	(3.6%)	 <0.0001	
All-cause	death/Any	TE	 70	(16.1%)	 18	(5.8%)	 4	(3.1%)	 2	(8.0%)	 <0.0001	
CV	death/Any	TE/Bleeding	 48	(12.0%)	 15	(4.9%)	 3	(2.4%)	 1	(4.2%)	 <0.001	
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Elderly	Patients	 	 	 	 	 	
N°	of	patients	 453	 276	 85	 21	 	
Major	Adverse	Events,	n	(%)	 	 	 	 	 	
Stroke/TIA	 7	(1.9%)	 3	(1.3%)	 0	 0	 0.749	
Bleeding	 8	(2.2%)	 3	(1.3%)	 0	 0	 0.693	
Any	TE	 17	(4.7%)	 7	(3.0%)	 5	(6.4%)	 1	(5.3%)	 0.451	
CV	death	 30	(7.0%)	 4	(1.5%)	 1	(1.2%)	 0	 0.002	
All-cause	death	 74	(16.3%)	 17	(6.2%)	 3	(3.5%)	 1	(4.8%)	 <0.0001	
All-cause	death/Any	TE	 91	(20.9%)	 24	(9.7%)	 8	(9.9%)	 2	(10.0%)	 <0.001	
CV	death/Any	TE/Bleeding	 54	(14.0%)	 16	(7.0%)	 6	(7.8%)	 1	(5.3%)	 0.032	
	 	 	 	 	 	
Paroxysmal	AF	 	 	 	 	 	
N°	of	patients	 202	 240	 146	 44	 	
Major	Adverse	Events,	n	(%)	 	 	 	 	 	
Stroke/TIA	 2	(1.2%)	 1	(0.4%)	 0	 0	 0.590	
Bleeding	 1	(0.6%)	 0	 1	(0.7%)	 0	 0.433	
Any	TE	 9	(5.3%)	 5	(2.2%)	 7	(4.9%)	 0	 0.179	
CV	death	 11	(5.6%)	 1	(0.4%)	 0	 0	 <0.001	
All-cause	death	 20	(9.9%)	 4	(1.7%)	 1	(0.7%)	 0	 <0.0001	
All-cause	death/Any	TE	 29	(15.3%)	 9	(4.0%)	 8	(5.6%)	 0	 <0.0001	
CV	death/Any	TE/Bleeding	 21	(11.8%)	 6	(2.7%)	 8	(5.6%)	 0	 <0.001	
	 	 	 	 	 	
High	Risk	(CHA2DS2-VASc≥2)	 	 	 	 	 	
N°	of	patients	 851	 710	 364	 67	 	
Major	Adverse	Events,	n	(%)	 	 	 	 	 	
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	 None	 Occasional	 Regular	 Intense	 p	
Stroke/TIA	 9	(1.3%)	 8	(1.3%)	 2	(0.6%)	 1	(1.8%)	 0.575	
Bleeding	 11	(1.6%)	 9	(1.5%)	 3	(0.9%)	 0	 0.819	
Any	TE	 32	(4.6%)	 23	(3.8%)	 18	(5.4%)	 3	(5.3%)	 0.723	
CV	death	 51	(6.3%)	 11	(1.6%)	 2	(0.6%)	 1	(1.5%)	 <0.0001	
All-cause	death	 114	(13.4%)	 32	(4.5%)	 6	(1.6%)	 3	(4.5%)	 <0.0001	
All-cause	death/Any	TE	 146	(18.0%)	 55	(8.7%)	 24	(7.0%)	 6	(10.0%)	 <0.0001	
CV	death/Any	TE/Bleeding	 93	(12.7%)	 42	(7.0%)	 23	(6.9%)	 4	(6.9%)	 <0.001	
Legend:	CV=	cardiovascular;	TE=	thromboembolic	event;	TIA=	transient	ischemic	attack.
8	
	 Table	S3:	M
ultivariable	Effect	of	Physical	Activity	on	M
ajor	Adverse	Events	According	to	Subgroups	
PA	
1-year	O
utcom
e	
M
ale	Patients	
Fem
ale	Patients	
Elderly	Patients	
	
	
O
R*	
95%
	CI	
p	
O
R*	
95%
	CI	
p	
O
R*	
95%
	CI	
p	
O
ccasional	
Stroke/TIA	
0.93	
[0.23-3.75]	
0.922	
1.27	
[0.36-4.43]	
0.706	
0.66	
[0.17-2.60]	
0.555	
	
Any	TE	
0.99	
[0.48-2.04]	
0.990	
0.59	
[0.26-1.32]	
0.193	
0.63	
[0.26-1.55]	
0.321	
	
Bleeding	
0.67	
[0.41-1.10]	
0.109	
0.78	
[0.47-1.31]	
0.346	
0.45	
[0.26-0.76]	
0.003	
	
CV	death/	
Any	TE/Bleeding	
0.55	
[0.34-0.88]	
0.011	
0.38	
[0.21-0.69]	
0.001	
0.46	
[0.26-0.83]	
0.008	
Regular	
Stroke/TIA	
0.54	
[0.10-2.96]	
0.470	
NA	
NA	
-	
NA	
NA	
-	
	
Any	TE	
1.47	
[0.74-2.91]	
0.269	
0.15	
[0.02-1.15]	
0.036	
1.39	
[0.49-3.88]	
0.215	
	
Bleeding	
0.65	
[0.35-1.21]	
0.177	
0.93	
[0.45-1.90]	
0.840	
0.91	
[0.36-2.27]	
0.532	
	
CV	death/	
Any	TE/Bleeding	
0.48	
[0.29-0.81]	
0.005	
0.18	
[0.05-0.58]	
0.001	
0.52	
[0.21-1.25]	
0.139	
Intense	
Stroke/TIA	
1.25	
[0.14-11.36]	
0.841	
NA	
NA	
-	
NA	
NA	
-	
	
Any	TE	
0.66	
[0.15-2.94]	
0.581	
0.84	
[0.11-6.54]	
0.866	
1.12	
[0.14-8.92]	
0.912	
	
Bleeding	
0.34	
[0.08-1.46]	
0.131	
0.99	
[0.23-4.36]	
0.993	
0.73	
[0.09-5.56]	
0.761	
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	 PA	
1-year	O
utcom
e	
M
ale	Patients	
Fem
ale	Patients	
Elderly	Patients	
	
CV	death/	
Any	TE/Bleeding	
0.28	
[0.08-0.92]	
0.025	
0.32	
[0.04-2.41]	
0.244	
0.34	
[0.04-2.61]	
0.278	
Legend:	*Analysis	presented	is	unadjusted	univariate	logistic	analysis.	CI=	confidence	interval;	CV=	cardiovascular;	NA=	not	available;	OR=	odds	
ratio;	TE=	throm
boem
bolism
;	TIA=	transient	ischem
ic	attack.	
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	 Table	S3	(Continued):	M
ultivariable	Effect	of	Physical	Activity	on	M
ajor	Adverse	Events	According	to	Subgroups	
PA	
1-year	O
utcom
e	
Paroxysm
al	AF	
High	Risk	(CHA
2 DS
2 -VASc≥2)	
	
	
O
R*	
95%
	CI	
p	
O
R*	
95%
	CI	
p	
O
ccasional	
Stroke/TIA	
0.38	
[0.03-4.18]	
0.408	
1.03	
[0.39-2.68]	
0.953	
	
Any	TE	
0.41	
[0.13-1.24]	
0.103	
0.82	
[0.48-1.43]	
0.491	
	
Bleeding	
0.58	
[0.25-1.35]	
0.200	
0.64	
[0.44-0.92]	
0.017	
	
CV	death/	
Any	TE/Bleeding	
0.21	
[0.08-0.52]	
<0.001	
0.51	
[0.35-0.75]	
<0.001	
Regular	
Stroke/TIA	
NA	
NA	
-	
0.46	
[0.10-2.13]	
0.308	
	
Any	TE	
0.92	
[0.33-2.54]	
0.875	
1.18	
[0.65-2.13]	
0.588	
	
Bleeding	
2.73	
[0.87-8.57]	
0.074	
0.96	
[0.60-1.55]	
0.975	
	
CV	death/	
Any	TE/Bleeding	
0.45	
[0.19-1.04]	
0.056	
0.51	
[0.31-0.82]	
0.005	
Intense	
Stroke/TIA	
-	
-	
-	
1.37	
[0.17-10.98]	
0.768	
	
Any	TE	
-	
-	
-	
1.16	
[0.34-3.90]	
0.815	
	
Bleeding	
-	
-	
-	
0.85	
[0.30-2.43]	
0.771	
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	 PA	
1-year	O
utcom
e	
Paroxysm
al	AF	
High	Risk	(CHA
2 DS
2 -VASc≥2)	
	
CV	death/	
Any	TE/Bleeding	
-	
-	
-	
0.51	
[0.18-1.44]	
0.196	
Legend:	*Analysis	presented	is	unadjusted	univariate	logistic	analysis.	CI=	confidence	interval;	CV=	cardiovascular;	NA=	not	available;	OR=	odds	
ratio;	TE=	throm
boem
bolism
;	TIA=	transient	ischem
ic	attack.	
